enGene Therapeutics downgraded by Citizens
$ENGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citizens downgraded enGene Therapeutics from Mkt Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2026 | $4.00 | Strong Buy → Outperform | Raymond James |
| 5/8/2026 | $4.00 | Overweight → Neutral | Piper Sandler |
| 5/8/2026 | Buy → Neutral | Guggenheim | |
| 5/8/2026 | Mkt Outperform → Mkt Perform | Citizens | |
| 5/8/2026 | $2.00 | Outperform → Market Perform | Leerink Partners |
| 5/8/2026 | $2.00 | Overweight → Equal Weight | Wells Fargo |
| 5/8/2026 | Overweight → Equal-Weight | Morgan Stanley | |
| 5/8/2026 | Outperform → Perform | Oppenheimer |
54% complete response (CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%) Kaplan-Meier estimate of 12-month CR rate is 25% enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m. ET enGene Therapeutics Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND t
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ
LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 Biologics License Application (BLA) submission for detalimogene planned for 2H 2026 Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028 Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter en
SCHEDULE 13G/A - enGene Therapeutics Inc. (0001980845) (Subject)
SCHEDULE 13G/A - enGene Therapeutics Inc. (0001980845) (Subject)
SCHEDULE 13G - enGene Therapeutics Inc. (0001980845) (Subject)
Raymond James downgraded enGene Therapeutics from Strong Buy to Outperform and set a new price target of $4.00
Piper Sandler downgraded enGene Therapeutics from Overweight to Neutral and set a new price target of $4.00
Guggenheim downgraded enGene Therapeutics from Buy to Neutral
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
54% complete response (CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%) Kaplan-Meier estimate of 12-month CR rate is 25% enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m. ET enGene Therapeutics Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND t
Low rates of treatment-related adverse events (42%) and dose interruptions (1.6%) Emerging detalimogene profile supports potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CIS LEGEND trial pivotal cohort completed enrollment with 125 patients, exceeding target enGene to host conference call and webcast at 8:00 a.m. ET enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The live call can be accessed by registering as a participant here. Upon registration, participants will receive conference dial-in information. A link to th
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula
Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board Management promotions strengthen clinical and regulatory operations Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transit
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co